Pacira reported $181.1M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Astellas Pharma JPY 505.79B 46.5B Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Ironwood Pharmaceuticals USD 85.24M 5.3M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Ligand Pharmaceuticals USD 47.63M 2.3M Jun/2025
Novo Nordisk 76.86B 1.23B Jun/2025
Pacira USD 181.1M 12.18M Jun/2025
Perrigo USD 1.06B 20M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Supernus Pharmaceuticals USD 165.5M 15.7M Jun/2025
Teva Pharmaceutical Industries USD 14.06B 0 Jun/2025
Xeris Pharmaceuticals USD 71.54M 11.44M Jun/2025
Zoetis USD 2.46B 240M Jun/2025